3017 Terasaki Life Sciences Building
610 Charles E. Young Drive East
Los Angeles, CA 90095
Recent Publications
Stem cell engineering for the generation of allogeneic CAR-directed natural killer T cells targeting endometrial carcinoma
Experimental Hematology & Oncology
AlloMCAR-NKT cells have to potential to provide a safe and effective off-the-shelf cellular immunotherapy for the treatment of uterine/endometrial carcinomas as well as other solid tumors characterized by an immunosuppressive microenvironment.
Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells
Med
Exploriong the alternative approach of using allogenic CAR-engineered invariant natural killer T (AlloCAR-NKT) cells to not only combat chemo resistant ovarian cancer tumors but also remodel the tumor micro environment.
Tumor extracellular vesicle surface Protein-mRNA integration assay for early detection of epithelial ovarian cancer
eBioMedicine
Tumour-derived extracellular vesicles (EVs) are a promising potential biomarker for epithelial ovarian cancer. Here we deveopled a Surface Protein-mRNA Integration (SPRI) Assay for early detection.
A case series of four patients with recurrent ovarian granulosa cell tumors treated with CDK4/6 inhibitors and estrogen blockade in a pilot study
European Journal of Gynaecological Oncology
There is currently no established optimal treatment for advanced or recurrent granulosa cell tumors (GCTs), making management challenging. Given the success of CDK4/6 inhibitors in hormone receptor-positive breast cancer, we explored their use in GCTs.
Protocol to profile tumor and microenvironment from ovarian cancer patient samples and evaluate cell-based therapy using in vitro killing assays
STAR Protocols
Protocol to characterize primary ovarian cancer patient samples and a detalied design and evaluation of various cell-based immunotherapies aimed at targeting primary tumors and the tumor microenvironment through in vitro killing assays.
Inability of ovarian cancers to upregulate their MHC-class I surface expression marks their aggressiveness and increased susceptibility to NK cell-mediated cytotoxicity
Cancer Immunology, Immunotherapy
We extended our previous observations with other tumor models to study seven ovarian tumor cell lines-OVCAR3, OVCAR4, OVCAR8, SKOV3, Kuramochi, OAW28, and CaOV3. We found that NK cells targeted and killed poorly differentiated OVCAR8 and CAOV3; these two tumor lines express lower MHC-class I and higher CD44 surface receptors. OVCAR3 and OVCAR4 were more resistant to NK cell-mediated cytotoxicity, and SKOV3, Kuramochi and OAW28 had intermediate sensitivity to NK cell-mediated cytotoxicity, likely representing well-differentiated and moderately differentiated ovarian tumor cell lines, respectively.
cfTrack: Exome-wide mutation analysis of cell-free DNA to simultaneously monitor the full spectrum of cancer treatment outcomes: MRD, recurrence, and evolution
Clinical Cancer Research
Cell-free DNA (cfDNA) offers a non-invasive approach to monitor cancer. Here we develop a method using whole-exome sequencing (WES) of cfDNA for simultaneously monitoring the full spectrum of cancer treatment outcomes, including MRD, recurrence, evolution, and second primary cancers.
SUPPORT RESEARCH
Donate
​Every donation is gratefully accepted and will be put to use on the work of the lab. There are many ways to donate, and all make a difference. If you share our passion for finding better treatments for women’s cancer, please consider giving hope by donating to this important cause.